Literature DB >> 20406234

Intratumoral patterns of genomic imbalance in glioblastomas.

Sumihito Nobusawa1, Joel Lachuer, Anne Wierinckx, Young Ho Kim, Jian Huang, Catherine Legras, Paul Kleihues, Hiroko Ohgaki.   

Abstract

Glioblastomas are morphologically and genetically heterogeneous, but little is known about the regional patterns of genomic imbalance within glioblastomas. We recently established a reliable whole genome amplification (WGA) method to randomly amplify DNA from paraffin-embedded histological sections with minimum amplification bias [Huang et al (J Mol Diagn 11: 109-116, 2009)]. In this study, chromosomal imbalance was assessed by array comparative genomic hybridization (CGH; Agilent 105K, Agilent Technologies, Santa Clara, CA, USA), using WGA-DNA from two to five separate tumor areas of 14 primary glioblastomas (total, 41 tumor areas). Chromosomal imbalances significantly differed among glioblastomas; the only alterations that were observed in > or =6 cases were loss of chromosome 10q, gain at 7p and loss of 10p. Genetic alterations common to all areas analyzed within a single tumor included gains at 1q32.1 (PIK3C2B, MDM4), 4q11-q12 (KIT, PDGFRA), 7p12.1-11.2 (EGFR), 12q13.3-12q14.1 (GLI1, CDK4) and 12q15 (MDM2), and loss at 9p21.1-24.3 (p16(INK4a)/p14(ARF)), 10p15.3-q26.3 (PTEN, etc.) and 13q12.11-q34 (SPRY2, RB1). These are likely to be causative in the pathogenesis of glioblastomas (driver mutations). In addition, there were numerous tumor area-specific genomic imbalances, which may be either nonfunctional (passenger mutations) or functional, but constitute secondary events reflecting progressive genomic instability, a hallmark of glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406234     DOI: 10.1111/j.1750-3639.2010.00395.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  29 in total

Review 1.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 2.  Molecular heterogeneity of glioblastoma and its clinical relevance.

Authors:  Katalin Eder; Bernadette Kalman
Journal:  Pathol Oncol Res       Date:  2014-08-27       Impact factor: 3.201

3.  Targeting PI3K in Cancer: Any Good News?

Authors:  Miriam Martini; Elisa Ciraolo; Federico Gulluni; Emilio Hirsch
Journal:  Front Oncol       Date:  2013-05-08       Impact factor: 6.244

Review 4.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

5.  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

Authors:  Ren-Yuan Bai; Verena Staedtke; Colette M Aprhys; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2011-07-15       Impact factor: 12.300

Review 6.  Molecular targeting of glioblastoma: Drug discovery and therapies.

Authors:  Ren-Yuan Bai; Verena Staedtke; Gregory J Riggins
Journal:  Trends Mol Med       Date:  2011-03-14       Impact factor: 11.951

Review 7.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

8.  Glioblastoma Stem Cells: A Neuropathologist's View.

Authors:  Roger E McLendon; Jeremy N Rich
Journal:  J Oncol       Date:  2010-11-01       Impact factor: 4.375

9.  Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.

Authors:  Hannah Johnson; Amanda M Del Rosario; Bryan D Bryson; Mark A Schroeder; Jann N Sarkaria; Forest M White
Journal:  Mol Cell Proteomics       Date:  2012-09-10       Impact factor: 5.911

10.  Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation.

Authors:  Lisandra Muñoz-Hidalgo; Teresa San-Miguel; Javier Megías; Rosario Gil-Benso; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Hum Cell       Date:  2019-08-06       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.